Methotrexate (MTX), the anchor drug in the current treatment strategy for rheumatoid arthritis
(RA), was first approved for treatment of RA in Japan in 1999 at the recommended dose of 6 …

The unique genetic, environmental and medical backgrounds of people in Japan might
influence the effectiveness and safety of biologic agents in patients with rheumatoid arthritis …

The prognosis of patients with connective tissue disease (CTD) has improved significantly in
recent years, but interstitial lung disease (ILD) associated with connective tissue disease …

Background Tumour necrosis factor (TNF) inhibitors enable tight control of disease activity in
patients with rheumatoid arthritis (RA). Discontinuation of TNF inhibitors after acquisition of …

OBJECTIVE: Acute/subacute interstitial pneumonia (A/SIP) in patients with polymyositis/
dermatomyositis (PM/DM) is frequently fatal within months despite high dose prednisolone …

Consensus statement for the diagnosis and treatment of drug-induced lung injuries. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu …

Objective. To compare tumor necrosis factor-α (TNF-α) inhibitors to nonbiological disease-
modifying antirheumatic drugs (DMARD) for the risk of serious infection in Japanese patients …

Objective To report the primary (1‐year) results from PREVENT, the first phase III study
evaluating secukinumab in patients with active nonradiographic axial spondyloarthritis …

Objective To evaluate the efficacy and safety of tocilizumab, an interleukin-6 receptor
antibody, in patients with adult-onset Still's disease. Methods In this double-blind …

Objective To establish predictive models for mortality in patients with polymyositis/
dermatomyositis–associated interstitial lung disease (PM/DM‐ILD) using a combination of …